Replimune Group, Inc. (NASDAQ: REPL), a clinical-stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today presented final first-in-human data for ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Replimune received rejections in ...
一部の結果でアクセス不可の可能性があるため、非表示になっています。
アクセス不可の結果を表示する